Abstract:<p>Chemotherapeutic strategy has been widely used for treating malignance by targeting irregular expressed or mutant proteins with small molecular inhibitors (SMIs) or monoclonal antibodies (mAbs). However, most intracellular proteins lack of active sites or antigens where SMIs or mAbs bind with, and are called as non-druggable targets for a long time. From the first year of this century, PROteolysis-TArgeting Chimeras (PROTACs) has emerged to be a promising approach for proteins, including those non-druggable ones, such as transcriptional factors and scaffold proteins. The first generation of peptide-based PROTACs adopts β-TrCP and VHL as E3 ligases, but the cellular permeability and chemical stability issues restrict their clinical application. The second generation of small molecule-based PROTACs adopts MDM2, VHL, IAPs and Cereblon as E3 ligases have been tensely studied. To date, the targets of PROTACs including those overexpressed oncogenic proteins such as ER, AR and BRDs, disease-relevant fusion proteins such as NPM/EML4-ALK and BCL-ABL, cancer-driven mutant proteins such as EGFR, kinases such as CDKs and RTKs. The major disadvantage of PROTACs is the noncancer specificity and relative higher toxicity, due to its catalytic role. To overcome this, we and other have recently developed several similar light-controllable PROTACs, termed as the third generation controllable PROTACs. The degradation of targets by those PROTACs can be triggered by UVA or visible light, providing a tool box for further PROTACs design. Here in this review, we introduce the historical milestones and prospective for further PROTACs development in clinical use.</p>

Development of Visible-Light-activatable Photocaged PROTACs

Light-Induced Protein Degradation With Photocaged Protacs

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Light-induced Control of Protein Destruction by Opto-Protac.

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation

Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.

PHOTACs enable optical control of protein degradation

Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation

A Photoactivatable Upconverting Nanodevice Boosts Lysosomal Escape of PROTAC Degraders for Enhanced Combination Therapy

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

PROTACs: A novel strategy for cancer therapy

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery

Precise Modulation of Protein Degradation by Smart PROTACs

Discovery of an Activatable Near-Infrared Fluorescent and Theranostic PROTAC for Tumor-Targeted Detecting and Degrading of BRD4

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors

Light-Activatable Photochemically Targeting Chimeras (PHOTACs) Enable the Optical Control of Targeted Protein Degradation of HDAC6

A Photoactivatable Upconverting Nanodevice Boosts the Lysosomal Escape of PROTAC Degraders for Enhanced Combination Therapy

Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets

Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

New Generation of PROTACs: Advancement in Light‐Responsive and Self‐Assembled PROTACs